Covered recipient · General Payments record
RONALD L SCHWARTZ
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$129,717.37
202 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $75,550.00 | 39 |
| Travel and Lodging | $27,421.69 | 64 |
| Consulting Fee | $24,237.50 | 8 |
| Food and Beverage | $2,508.18 | 91 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $127,472.51 | 152 |
| E.R. Squibb & Sons, L.L.C. | $596.84 | 3 |
| GE HEALTHCARE | $500.00 | 1 |
| ABBVIE INC. | $268.63 | 12 |
| Eisai Inc. | $247.75 | 9 |
| Octapharma USA, Inc. | $122.72 | 6 |
| ACADIA Pharmaceuticals Inc | $117.11 | 5 |
| Biogen, Inc. | $115.33 | 1 |
| Novartis Pharmaceuticals Corporation | $76.75 | 3 |
| GENZYME CORPORATION | $30.95 | 1 |
| Alexion Pharmaceuticals, Inc. | $30.31 | 1 |
| PFIZER INC. | $29.15 | 2 |
| UCB, Inc. | $23.44 | 1 |
| Axsome Therapeutics, Inc. | $22.10 | 1 |
| Lundbeck LLC | $17.09 | 1 |
| Boston Scientific Corporation | $16.39 | 1 |
| Amgen Inc. | $15.33 | 1 |
| Janssen Biotech, Inc. | $14.97 | 1 |
Page 4 of 5; records 151–200 of 202 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
RONALD L SCHWARTZ
NPI 1780793331 · CMS profile ID 307599
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology
HATTIESBURG, MS
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 4 of 5; records 151–200 of 202 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1780793331?year=2025&recipient=provider&page=4#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- RONALD L SCHWARTZ, NPI 1780793331, CMS profile ID 307599. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 202 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1780793331?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). RONALD L SCHWARTZ, NPI 1780793331, CMS profile ID 307599. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 202 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1780793331?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- RONALD L SCHWARTZ, NPI 1780793331, CMS profile ID 307599, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 5; records 151–200 of 202 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1780793331?year=2025&recipient=provider&page=4#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
202 matching records · $129,717.37 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 151–200 of 202.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Lilly USA, LLC | $12.50 | 03/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186848629 | CMS |
| Lilly USA, LLC | $9.86 | 03/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186859231 | CMS |
| Octapharma USA, Inc. | $14.97 | 03/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1245083187 | CMS |
| Lilly USA, LLC | $2,100.00 | 03/04/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186889989 | CMS |
| Lilly USA, LLC | $1,850.00 | 03/04/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186922900 | CMS |
| Eisai Inc. | $27.91 | 03/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1244509511 | CMS |
| Lilly USA, LLC | $129.99 | 02/27/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186848617 | CMS |
| Lilly USA, LLC | $1,813.37 | 02/27/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186889975 | CMS |
| Lilly USA, LLC | $2,361.36 | 02/27/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186922884 | CMS |
| Lilly USA, LLC | $90.35 | 02/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186935476 | CMS |
| ACADIA Pharmaceuticals Inc | $28.16 | 02/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1247798572 | CMS |
| PFIZER INC. | $14.70 | 02/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1231373443 | CMS |
| ACADIA Pharmaceuticals Inc | $19.39 | 01/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1247798568 | CMS |
| Octapharma USA, Inc. | $23.44 | 01/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1245083185 | CMS |
| Lilly USA, LLC | $12.69 | 01/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186889987 | CMS |
| Lilly USA, LLC | $7.00 | 01/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186922898 | CMS |
| Lilly USA, LLC | $1,850.00 | 01/21/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186848627 | CMS |
| Lilly USA, LLC | $2,100.00 | 01/21/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186889983 | CMS |
| Lilly USA, LLC | $53.20 | 01/17/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186922896 | CMS |
| Octapharma USA, Inc. | $19.48 | 01/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1245083183 | CMS |
| ABBVIE INC. | $25.45 | 01/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1204137763 | CMS |
| Lilly USA, LLC | $2,100.00 | 01/16/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186898977 | CMS |
| Lilly USA, LLC | $1,325.00 | 01/16/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186898979 | CMS |
| Eisai Inc. | $32.13 | 01/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1244509509 | CMS |
| Lilly USA, LLC | $1,850.00 | 01/15/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186859227 | CMS |
| Lilly USA, LLC | $124.99 | 01/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186859233 | CMS |
| Lilly USA, LLC | $3,839.18 | 01/15/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186872177 | CMS |
| Lilly USA, LLC | $1,698.47 | 01/15/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186889973 | CMS |
| Lilly USA, LLC | $287.90 | 01/15/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186922882 | CMS |
| Lilly USA, LLC | $2,100.00 | 01/15/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186922888 | CMS |
| Alexion Pharmaceuticals, Inc. | $30.31 | 01/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202915607 | CMS |
| Lilly USA, LLC | $19.26 | 01/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186872181 | CMS |
| Lilly USA, LLC | $13.80 | 01/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186872185 | CMS |
| Lilly USA, LLC | $331.80 | 01/10/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186872187 | CMS |
| Lilly USA, LLC | $8.87 | 01/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186935472 | CMS |
| Lilly USA, LLC | $1,850.00 | 01/09/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186859225 | CMS |
| Lilly USA, LLC | $29.89 | 01/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186859229 | CMS |
| Lilly USA, LLC | $28.00 | 01/09/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186872183 | CMS |
| Lilly USA, LLC | $109.20 | 01/09/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186889985 | CMS |
| Lilly USA, LLC | $16.62 | 01/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186898981 | CMS |
| Lilly USA, LLC | $35.54 | 01/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186898983 | CMS |
| Lilly USA, LLC | $78.00 | 01/09/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186898985 | CMS |
| Lilly USA, LLC | $39.06 | 01/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186909520 | CMS |
| Lilly USA, LLC | $11.00 | 01/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186922892 | CMS |
| Lilly USA, LLC | $164.82 | 01/09/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186922894 | CMS |
| Lilly USA, LLC | $2,100.00 | 01/09/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186935470 | CMS |
| Lilly USA, LLC | $2,100.00 | 01/08/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186922890 | CMS |
| Lilly USA, LLC | $181.54 | 01/06/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186898959 | CMS |
| Lilly USA, LLC | $870.08 | 01/06/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186898961 | CMS |
| Lilly USA, LLC | $19.52 | 01/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186909518 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $3,004.87 | 1 |
| PY2025 | Principal investigator | $250,861.10 | 38 |
| PY2024 | Recipient | $2,603.10 | 1 |
| PY2024 | Principal investigator | $598,132.36 | 36 |
| PY2023 | Principal investigator | $1,027,486.78 | 32 |
| PY2022 | Principal investigator | $652,797.27 | 31 |
| PY2021 | Principal investigator | $743,347.47 | 27 |
| PY2020 | Principal investigator | $718,371.30 | 49 |
| PY2019 | Recipient | $124.18 | 1 |
| PY2019 | Principal investigator | $1,218,778.20 | 114 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
39 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Janssen Research & Development, LLC | $14,976.00 | 12/29/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175398665 |
| Principal investigator 1 | Janssen Research & Development, LLC | $871.00 | 12/22/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175398721 |
| Principal investigator 1 | Eisai Inc. | $3,008.70 | 12/15/2025 | Non-covered Recipient Entity Hattiesburg Clinic-Laboratory | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1244559028 |
| Principal investigator 1 | Janssen Research & Development, LLC | $23,467.00 | 12/15/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175398701 |
| Principal investigator 1 | Eisai Inc. | $2,988.90 | 11/17/2025 | Non-covered Recipient Entity Hattiesburg Clinic-Laboratory | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1244559032 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,766.00 | 11/13/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175398558 |
| Principal investigator 1 | Janssen Research & Development, LLC | $779.00 | 11/03/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175398630 |
| Principal investigator 1 | Novo Nordisk AS | $950.00 | 10/29/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | NN6535-4725 | No dispute reported | 06/30/2026 | 1213744290 |
| Principal investigator 1 | Eisai Inc. | $1,000.00 | 10/21/2025 | Non-covered Recipient Entity Hattiesburg Clinic-Laboratory | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1244559030 |
| Principal investigator 1 | Eisai Inc. | $2,988.90 | 10/20/2025 | Non-covered Recipient Entity Hattiesburg Clinic-Laboratory | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1244559026 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,640.00 | 09/29/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175398597 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,370.46 | 09/24/2025 | Non-covered Recipient Entity Hattiesburg Clinic Neurology | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimers Disease (MINDSET 2) | No dispute reported | 06/30/2026 | 1235997003 |
| Principal investigator 1 | Eisai Inc. | $28,927.80 | 09/15/2025 | Non-covered Recipient Entity Hattiesburg Clinic-Laboratory | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1244559020 |
| Principal investigator 1 | Janssen Research & Development, LLC | $871.00 | 09/05/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175398581 |
| Principal investigator 1 | Novo Nordisk AS | $3,005.56 | 08/22/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | NN6535-4725 | No dispute reported | 06/30/2026 | 1213726540 |
| Principal investigator 1 | Eisai Inc. | $3,634.20 | 08/11/2025 | Non-covered Recipient Entity Hattiesburg Clinic-Laboratory | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1244559018 |
| Principal investigator 1 | Janssen Research & Development, LLC | $871.00 | 08/11/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175398671 |
| Principal investigator 1 | Eisai Inc. | $2,988.90 | 07/21/2025 | Non-covered Recipient Entity Hattiesburg Clinic-Laboratory | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1244559022 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $16,580.27 | 07/14/2025 | Non-covered Recipient Entity Hattiesburg Clinic Neurology | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimers Disease (MINDSET 2) | No dispute reported | 06/30/2026 | 1235997001 |
| Principal investigator 1 | Novo Nordisk AS | $2,500.00 | 07/10/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | NN6535-4725 | No dispute reported | 06/30/2026 | 1213795178 |
| Principal investigator 1 | Eisai Inc. | $5,934.60 | 07/07/2025 | Non-covered Recipient Entity Hattiesburg Clinic-Laboratory | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1244559024 |
| Principal investigator 1 | Janssen Research & Development, LLC | $618.00 | 07/07/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175398610 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $3,797.88 | 06/25/2025 | Non-covered Recipient Entity Hattiesburg Clinic Family Practice | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Agitation Associated with Alzheimers Disease | No dispute reported | 06/30/2026 | 1235997013 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,935.00 | 06/23/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175398695 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,060.00 | 06/06/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175398574 |
| Principal investigator 1 | Biogen, Inc. | $858.00 | 05/21/2025 | Non-covered Recipient Entity Hattiesburg Clinic | A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease | No dispute reported | 06/30/2026 | 1236947410 |
| Principal investigator 1 | Janssen Research & Development, LLC | $871.00 | 05/12/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175398636 |
| Principal investigator 1 | Janssen Research & Development, LLC | $44,649.00 | 05/08/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175398688 |
| Principal investigator 1 | Novo Nordisk AS | $6.26 | 05/01/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | NN6535-4725 | No dispute reported | 06/30/2026 | 1213818669 |
| Principal investigator 1 | Novo Nordisk AS | $950.00 | 04/21/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | NN6535-4725 | No dispute reported | 06/30/2026 | 1213731761 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,383.00 | 04/17/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175398570 |
| Principal investigator 1 | Eli Lilly and Company | $42,364.00 | 04/01/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE | No dispute reported | 06/30/2026 | 1187883518 |
| Principal investigator 1 | Eli Lilly and Company | $631.41 | 03/26/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE | No dispute reported | 06/30/2026 | 1187882890 |
| Principal investigator 1 | Eli Lilly and Company | $4.26 | 03/26/2025 | Non-covered Recipient Entity SOUTHERN ENDOCRINOLOGY ASSOCIATES PA | A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE | No dispute reported | 06/30/2026 | 1187889848 |
| Recipient | Eli Lilly and Company | $3,004.87 | 02/25/2025 | Covered Recipient Physician | A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE | No dispute reported | 06/30/2026 | 1187872697 |
| Principal investigator 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,816.75 | 02/19/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF AVP-786 (DEUDEXTROMETHORPHAN HYDROBROMIDE [D6-DM]/QUINIDINE SULFATE [Q]) FOR THE TREATMENT OF AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMERS TYPE | No dispute reported | 06/30/2026 | 1225335529 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,386.00 | 02/10/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC PA | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175398683 |
| Principal investigator 1 | Novo Nordisk AS | $2,161.25 | 01/31/2025 | Non-covered Recipient Entity HATTIESBURG CLINIC | NN6535-4725 | No dispute reported | 06/30/2026 | 1213839436 |
| Principal investigator 1 | Biogen, Inc. | $3,250.00 | 01/28/2025 | Non-covered Recipient Entity Hattiesburg Clinic | Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205 | No dispute reported | 06/30/2026 | 1236948096 |